期刊
MOLECULAR THERAPY-NUCLEIC ACIDS
卷 18, 期 -, 页码 590-604出版社
CELL PRESS
DOI: 10.1016/j.omtn.2019.09.019
关键词
-
资金
- National Natural Science Foundation of China [61871160, 61502125]
- Heilongjiang Postdoctoral Fund [LBH-TZ20, LBH-Z15179]
- China Postdoctoral Science Foundation [2018T110315, 2016M590291]
Although our knowledge of human diseases has increased dramatically, the molecular basis, phenotypic traits, and therapeutic targets of most diseases still remain unclear. An increasing number of studies have observed that similar diseases often are caused by similar molecules, can be diagnosed by similar markers or phenotypes, or can be cured by similar drugs. Thus, the identification of diseases similar to known ones has attracted considerable attention worldwide. To this end, the associations between diseases at the molecular, phenotypic, and taxonomic levels were used to measure the pairwise similarity in diseases. The corresponding performance assessment strategies for these methods involving the terms category-based, simulated-patient-based, and benchmark-data-based were thus further emphasized. Then, frequently used methods were evaluated using a benchmark-data-based strategy. To facilitate the assessment of disease similarity scores, researchers have designed dozens of tools that implement these methods for calculating disease similarity. Currently, disease similarity has been advantageous in predicting noncoding RNA (ncRNA) function and therapeutic drugs for diseases. In this article, we review disease similarity methods, evaluation strategies, tools, and their applications in the biomedical community. We further evaluate the performance of these methods and discuss the current limitations and future trends for calculating disease similarity.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据